Valuation loss on securities in the second quarter of the fiscal year ending September 2026
Fuji Pharma Co.,Ltd. (the Company)
Shares of Alvotech Holding S.A. (NASDAQ-listed)
The significant decline in Alvotech Holding S.A.'s share price
¥3,519 million (valuation loss on securities)
Cumulative consolidated period for the second quarter of the fiscal year ending September 2026 (1 October 2025 to 31 March 2026)
There is no change to the consolidated earnings forecast for the fiscal year ending September 2026.
The valuation loss on securities will fluctuate depending on the share price at the end of the third quarter of the fiscal year ending September 2026 or at the end of that fiscal year. There is no change to the consolidated earnings forecast for the fiscal year ending September 2026.
| Item | Details |
|---|---|
| Event name | Valuation loss on securities in the second quarter of the fiscal year ending September 2026 |
| Subject Entity | Fuji Pharma Co.,Ltd. (the Company) |
| Target Locations / Products | Shares of Alvotech Holding S.A. (NASDAQ-listed) |
| Cause | The significant decline in Alvotech Holding S.A.'s share price |
| Amount of Impact on Business Performance | ¥3,519 million (valuation loss on securities) |
| Accounting period in which recognized | Cumulative consolidated period for the second quarter of the fiscal year ending September 2026 (1 October 2025 to 31 March 2026) |
| Impact on Earnings Forecast | There is no change to the consolidated earnings forecast for the fiscal year ending September 2026. |
| Outlook | The valuation loss on securities will fluctuate depending on the share price at the end of the third quarter of the fiscal year ending September 2026 or at the end of that fiscal year. There is no change to the consolidated earnings forecast for the fiscal year ending September 2026. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The share price of Alvotech Holding S.A., the global licensor for the biosimilar business, declined significantly.